Objective: To evaluate prospectively the efficacy and safety of sorafenib, which has been the firstline treatment for advanced hepatocellular carcinoma (HCC), in Japanese HCC patients (pts) with not only Child-Pugh (C-P) A class but also C-P B class. Methods: Sorafenib was administered orally at the dose of 400 mg twice daily for pts with HCC and liver function of C-P score of 5-8. Administration was continued until the detection of disease progression or appearance of unacceptable toxicity. The primary endpoint was time to progression (TTP), and toxicity and the secondary endpoints included objective response, overall survival (OS).
Introduction
Hepatocellular carcinoma (HCC) is one of the most commonly occurring cancers worldwide (1) . Surgical resection, liver transplantation and local ablation therapy are considered as curative treatment for HCC. Transcatheter arterial chemoembolization (TACE) is the effective treatment for non-curative HCC (2, 3) . However, despite of many progress, survival remains poor because of high rate of recurrence. Based on the results from two Phase III trials using sorafenib, an oral multi-kinase inhibitor with antiproliferative and antiangiogenic effects, have demonstrated survival benefit in patients with advanced HCC compared with placebo (4, 5) . As a result, sorafenib has been established as the standard chemotherapy for advanced HCC.
In Japan, a Phase I study of sorafenib showed promising antitumor activity and a favorable toxicity profile (6) . Based on these results, sorafenib was approved by the Ministry of Health Labour and Welfare of Japan on 2008.
However, there are a few prospective studies in Japanese patients with advanced HCC receiving sorafenib. In addition, the survival benefit for the HCC patients with Child-Pugh (C-P) class B is controversial (7-9), because most patients enrolled in the two Phase III trials had Child-′Pugh A scores.
The aim of this study was to investigate efficacy and safety of sorafenib in Japanese patients with advanced HCC and C-P B class as well as C-P A class.
Patients and method

Eligibility criteria
The eligibility criteria for study enrollment were as follows:
(i) patients with pathologically or radiologically proven HCC, (ii) unsuitable for surgical resection, local ablation therapy or TACE, (iii) 20-79 years of age, (iv) an Eastern Cooperative Oncology Group performance status of 0-2, (v) an adequate bone marrow function (neutrophil ≥ 1500/mm ≦ 150IU/l, total bilirubin ≥ 3.0 mg/dl, serum albumin 2.8 g/dl); adequate renal function (serum creatinine < 1.5 mg/dl); and a C-P score of 5-8. Patients with a Child-Pugh B score of 9 were excluded from the study because of the risk of liver dysfunction due to sorafenib. Prior treatment such as resection, local ablation therapy and TACE, except systemic chemotherapy was permitted if the treatment was performed 30 days before enrollment.
This study was conducted with the approval of the institutional review board at all the participating hospitals in accordance with the provision of Declaration of Helsinki, Good Clinical Practice guidelines. The study is registered with the UMIN Clinical Trials Registry as 000002972. Informed consent was obtained from all participants including in this study.
Treatment
Sorafenib (Bayer Health Care Pharmaceuticals, West Haven, CT, USA) was administered orally at the dose of 400 mg twice daily. The treatment was repeated until the detection of disease progression, appearance of unacceptable toxicities, or patient's refusal. If Grade 3 or 4 non-hematological toxicities except increased level of serum gamma glutamyl transpeptidase/AST/ALT/creatinine, hypertension, constipation, hand foot skin reaction, Grade 4 neutropenia or thrombocytopenia and Grade 2 or 3 hypertension, serum AST/ALT levels of 10 times of upper limit of normal, Grade 4 pancreatic enzyme increases for more than 14 days or considered as life threatening, sorafenib was temporarily suspended until the toxicity recovered to Grade 1 or less, and the dose of sorafenib was reduced to 400 mg once a day. In a case of the course delay more than 28 days due to toxicity, the protocol treatment was discontinued. Patients were not allowed to receive concomitant therapy during the study but allowed to receive any anti-cancer therapy after the study.
Response and toxicity evaluation
The response after each course was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) ver 1.1. Physical examinations, complete blood cell counts, biochemistry tests, and urinalyses were assessed at least once every 2 weeks. Adverse events were evaluated according to the National Cancer Institute Common Toxicity Criteria, version 4.0.
Statistical analysis
We considered both efficacy and safety endpoints as primary. The efficacy primary endpoint was time to progression (TTP) and the secondary endpoints were overall survival (OS) and tumor response. The safety endpoints were frequency and severity of toxicity.
The required number of patients for a C-P A cohort was determined based on the TTP benefit observed in the SHARP trial (5). We set that median TTP of 5.5 months with sorafenib was the alternative hypothesis, and that median TTP of 2.8 months with placebo was the null hypothesis. Forty patients were sufficient to yield more than 90% power at the two-sided alpha level of 0.05. For a C-P B cohort, consecutive patient enrollment was performed during the same recruitment period as a C-P A cohort.
The TTP was calculated from the date of the first administration of sorafenib to the date of documented disease progression. The OS was calculated from the date of the first administration of sorafenib to the date of death or the date of the last follow-up. The median survival period and TTP were estimated using the Kaplan-Meier method. All the data were frozen on January 2013.
Results
From April 2010 to January 2012, 40 C-P A patients and 12 C-P B patients were enrolled in this study from 19 hospitals. Patient characteristics are shown in Table 1 .
Treatment
The reason for discontinuation of treatment were radiologically confirmed progressive disease (PD) (36 patients), clinically confirmed tumor progression before radiological confirmation (two patients), unacceptable toxicities (one patient), patients' request (one patient) in C-P A part, and radiologically confirmed PD (seven patients), clinically confirmed tumor progression before radiological progression (one patient), unacceptable toxicities (two patients), patients' request (two patients) in C-P B part. After finishing this study, in C-P A part, 15 patients received systemic chemotherapy, five patients received hepatic arterial infusion, four patients received TACE, four patients received radiation, and one patient received immunotherapy. On the other hand, in C-P B part, two patients received TACE, and three patients received hepatic arterial infusion.
Efficacy
The median TTP in patients with C-P A and C-P B were 3.3 months (95% CI 1.5-5.0), 3.2 months (95% CI 2.1-4.3), respectively (Fig. 1) . The median OS in patients with C-P A and C-P B were 13.4 months (95% CI 7.4-19.4), 7.4 months (3.8-11.0), respectively (Fig. 2) . In C-P A part, there was one case of complete response (CR), and three patients showed partial response (PR). Furthermore, 19 patients showed stable disease (SD), and 17 patients showed PD. The overall response rate was 10.0%, and the disease control rate was 57.5%.
One patient, who showed CR, had HCC in liver and lung before sorafenib therapy. Eight weeks after the start of sorafenib, none of the HCC lesions had been detected, and the patient continued on the treatment for 16 months.
In C-P B part, there was no case of CR nor PR, however, eight patients showed SD, and four patients showed PD. The overall response rate was 0.0%, and the disease control rate was 66.7%.
Toxicity
All the patients (40 patients in C-P A part and 12 patients in C-P B part) were assessable for adverse events. The treatment related adverse events are shown in Table 2 . C-P A patients less experienced Grade 3/4 toxicities than C-P B patients (77.5% vs. 91.6%). The Grade 3/4 toxicities in the C-P A and B patients, respectively, included thrombocytopenia (10% and 25%), hand foot skin reaction (27.5% and 16.7%), Erythema multiforme (0% and 16.7%), and upper gastrointestinal bleeding (0% and 16.7%). There were no treatment-related deaths in either group of patients.
Discussion
The aim of this study was to investigate the efficacy and safety of sorafenib in patients with HCC in C-P A and B class. As for primary efficacy endpoint, median TTP of 3.3 months in C-P A patients (95% CI 1.5-5.0 months) was containing the null hypothesis of 2.8 months. Recent studies, after the approval of sorafenib, have shown similar results and TTP tends to be worse in real life practice compared with Phase II or III pre-approval clinical trials (10) (11) (12) . Therefore, the hypothesis of TTP, which was based on the results of the SHARP study, may have been overestimated. Median TTP of C-P B patients was compatible with that of C-P A patients; median TTP was 3.2 months and 3.3 months, respectively. On the contrary, median OS was 13.4 months in C-P A patients and 7.4 months in C-P B patients, respectively. OS of C-P A patients were comparable to those reported previously (10) (11) (12) . Although similar TTPs were observed, the survival difference between C-P A patients and C-P B patients may be due to liver function that allowed patients to receive other treatments such as TACE, hepatic arterial infusion or systemic chemotherapy after sorafenib treatment, or natural history of HCC patients with C-P A or B after sorafenib treatment.
In terms of toxicity, sorafenib treatment was well tolerated in line with other clinical trials, with unexpected adverse events. As for all grade toxicity, there was no much difference between C-P A patients and C-P B patients. However, the proportion of C-P B patients experiencing Grade 3 or 4 adverse events were higher than that of C-P A patients, especially myelosuppression and upper gastrointestinal bleeding. In two cases of gastrointestinal bleeding, both patients had Child-Pugh B scores of 7 with varix rupture being the cause of bleeding. Bleeding was successfully stopped; however, neither patient could resume sorafenib therapy because of the deterioration of liver function. Careful attention was needed to prevent treatment-related death.
For C-P B patients, the survival benefit of sorafenib has been still controversial because the survival time was unsatisfactory. To prolong the survival in C-P B patients with advanced HCC, a new agent which has less toxic, especially for liver function, may expand life expectancy. Recently, new approach for controlling liver fibrosis has been developing (13) , and if this challenging can be applied for clinical practice, the combination therapy with sorafenib may achieve improvement of HCC patients.
In regard to analysis in C-P B patients, the current study has a limitation. It included only 12 patients of C-P B in this study. We adopted a limited recruitment schedule for C-P B patients, namely, C-P B patients were recruited limited at the same period of the enrollment of C-P A patients, because we had no experience to treat C-P B patients with sorafenib before this study. It was clarified that Abbreviation: ALB, albumin; AST, aspartate transaminase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGTP, gamma-glutamyl transpeptidase.
